Drug intelligence / Profile preview

LentinexHP

Development stage: Unknown
Lead developer: GlycaNova
Administration: Oral

Overview

LentinexHP is an **undenatured beta-glucan solution** evaluated as an *oral, add-on non-drug therapy* to improve quality of life in patients with stage IV metastatic colorectal cancer[5][3]. Beta-glucans are naturally occurring polysaccharides known for their immunomodulatory activity—primarily through activation of components of the innate immune system, such as macrophages, neutrophils, and natural killer (NK) cells. LentinexHP is being studied for its ability to enhance patient well-being during chemotherapy regimens[1][3][5]. The product's formulation targets support of immune function and mitigation of treatment-related fatigue and reduced quality of life during cancer treatment. The clinical sponsor and likely manufacturer is GlycaNova AS[3].

Brand names: LentinexHP

Beyond the preview

Go deeper on LentinexHP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LentinexHP.

Explore the full profile